Answers are grounded in this paper and cite their sources.
DESIGN BLUEPRINT — SIMULATED, NOT MEASURED — NOT BUILT. Design blueprint derived from 'Programmable White Blood Cells: A Two-Marker Specificity-Logic Design for Engineered T Cells' (DOI: 10.5281/zenodo.24108795). Specifies an engineered T cell in which a priming receptor for marker A induces a killing receptor for marker B, so firing requires both markers on the same target cell. Architecture, design parameters (Kd 5,000 and 4,000 copies per cell; diseased densities 50,000 A and 20,000 B), functional production outline with quality-control checkpoints, and operating budgets: discrimination ratio 25.0 versus 2.5 for a single-receptor design, 51.0-fold suppression on B-only healthy tissue, healthy-tissue cytokine risk index reduced 36.7-fold, persistence half-life 28 days, and burden coverage of 1.5x stated as thin. Safety case prints the dominant remaining risk (intended on-target activation, 2.27 x 10^10 activated cells), the source's five quantitative stopping conditions exactly, unbudgeted risks, acceptance criteria a future implementer must meet on measured values, and explicit non-claims: nothing built, synthesised, or tested; single-site equilibrium model limits on the face.
No takes yet. Share an insight, caveat, or question.
William Alexander Aldred (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: